We developed a microsimulation model to estimate the impact of treating patients with type 2 diabetes who use insulin with GLP-1 receptor agonists or SGLT-2 inhibitors in LMICs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.